ATE45498T1 - Immunmodulierendes arzneimittel basiert auf fc fragmenten menschlichen ig gs. - Google Patents

Immunmodulierendes arzneimittel basiert auf fc fragmenten menschlichen ig gs.

Info

Publication number
ATE45498T1
ATE45498T1 AT84402531T AT84402531T ATE45498T1 AT E45498 T1 ATE45498 T1 AT E45498T1 AT 84402531 T AT84402531 T AT 84402531T AT 84402531 T AT84402531 T AT 84402531T AT E45498 T1 ATE45498 T1 AT E45498T1
Authority
AT
Austria
Prior art keywords
fragments
subfragments
properties
human
igg
Prior art date
Application number
AT84402531T
Other languages
German (de)
English (en)
Inventor
Edgardo D Carosella
Jacques Armand
Original Assignee
Merieux Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merieux Inst filed Critical Merieux Inst
Application granted granted Critical
Publication of ATE45498T1 publication Critical patent/ATE45498T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT84402531T 1983-12-07 1984-12-07 Immunmodulierendes arzneimittel basiert auf fc fragmenten menschlichen ig gs. ATE45498T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8319568A FR2556219B1 (fr) 1983-12-07 1983-12-07 Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines
EP84402531A EP0147283B1 (fr) 1983-12-07 1984-12-07 Nouveau médicament immunomodulateur, à base de fragments Fc d'IgG Humaines

Publications (1)

Publication Number Publication Date
ATE45498T1 true ATE45498T1 (de) 1989-09-15

Family

ID=9294941

Family Applications (1)

Application Number Title Priority Date Filing Date
AT84402531T ATE45498T1 (de) 1983-12-07 1984-12-07 Immunmodulierendes arzneimittel basiert auf fc fragmenten menschlichen ig gs.

Country Status (7)

Country Link
US (1) US4719107A (enExample)
EP (1) EP0147283B1 (enExample)
JP (1) JPS60185726A (enExample)
AT (1) ATE45498T1 (enExample)
CA (1) CA1229791A (enExample)
DE (3) DE3479398D1 (enExample)
FR (1) FR2556219B1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62153300A (ja) * 1985-12-26 1987-07-08 Teijin Ltd ヒト免疫グロブリンＧＦｃ領域蛋白質およびその製造方法
US4925920A (en) * 1987-05-29 1990-05-15 Brigham And Women's Hospital Immunosuppressive polypeptides
US4814433A (en) * 1987-09-16 1989-03-21 Miles Inc. Method for obtaining a papain-free antibody fragment preparation
US5681566A (en) * 1988-10-24 1997-10-28 3I Research Exploitation Limited Antibody conjugates with two or more covalently linked FC regions
GB8824869D0 (en) * 1988-10-24 1988-11-30 Stevenson G T Synthetic antibody
FR2639231A1 (fr) * 1988-11-23 1990-05-25 Merieux Inst Utilisation de fragments fc d'immunoglobulines g humaines, de peptides analogues du fragment fc, ou d'immunoglobulines g humaines dans l'obtention d'un medicament preparatoire a l'administration chez l'homme, dans un but therapeutique ou de diagnostic, d'anticorps monoclonaux
US5328834A (en) * 1989-09-08 1994-07-12 Unisyn Technologies, Inc. Method for preparing immunoglobulin fragments
GB9009106D0 (en) * 1990-04-23 1990-06-20 3I Res Expl Ltd Processes and intermediates for synthetic antibody derivatives
US5230887A (en) * 1990-07-11 1993-07-27 Immune Network Research Ltd. Immune system stabilizers for prevention and therapy of disorders associated with immune system disfunction
US5219578A (en) * 1991-02-25 1993-06-15 Innovet, Inc. Composition and method for immunostimulation in mammals
US7425331B2 (en) * 2002-04-10 2008-09-16 Protalex, Inc. Protein A methods of use
US7211258B2 (en) * 2002-04-10 2007-05-01 Protalex, Inc. Protein A compositions and methods of use
AU2004247021A1 (en) * 2003-05-16 2004-12-23 Acorda Therapeutics Compositions and methods including a recombinant human MAB that promotes CNS remyelination
DE602004031772D1 (de) * 2003-12-04 2011-04-21 Abbott Biotherapeutics Corp Anti-ip-10-antikörper
US20080206246A1 (en) * 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
WO2007055916A2 (en) * 2005-11-07 2007-05-18 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
US8470318B2 (en) * 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US10167332B2 (en) * 2006-04-05 2019-01-01 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
JP4866467B2 (ja) 2007-01-30 2012-02-01 エピバックス インコーポレーテッド 調節性ｔ細胞エピトープ、組成物およびその使用
US20110150867A1 (en) * 2007-12-14 2011-06-23 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
MX2010011598A (es) * 2008-04-22 2010-12-15 Univ Rockefeller Metodos para identificar compuestos anti-inflamatorios.
SG10201913507SA (en) 2014-05-02 2020-02-27 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
ES2972740T3 (es) 2016-03-02 2024-06-14 Momenta Pharmaceuticals Inc Procedimientos relacionados con construcciones de Fc modificadas genéticamente
NZ749292A (en) 2016-05-23 2025-08-29 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
CN110650748B (zh) 2017-01-06 2024-01-02 动量制药公司 与经工程改造的Fc构建体相关的组合物和方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2222083B1 (enExample) * 1973-03-22 1976-05-14 Fontaine Michel
FR2267115B1 (enExample) * 1974-04-12 1977-11-10 Merieux Inst
DE2846412A1 (de) * 1978-10-25 1980-05-08 Behringwerke Ag Mittel zur behandlung allergischer reaktionen
DE2853453A1 (de) * 1978-12-11 1980-06-19 Behringwerke Ag Mittel zur therapie von immunkomplexerkrankungen
JPS5821623A (ja) * 1981-07-28 1983-02-08 Tetsuzo Sugizaki 抗原抗体複合体沈着疾患治療剤
JPS5821624A (ja) * 1982-04-06 1983-02-08 Tetsuzo Sugizaki 慢性関節リウマチの治療剤
EP0091760B1 (en) * 1982-04-09 1986-07-02 FUJIREBIO KABUSHIKI KAISHA also trading as FUJIREBIO INC. Anti immune complex antibody and preparation thereof
US4465670A (en) * 1982-07-23 1984-08-14 Dainippon Pharmaceutical Co., Ltd. Method for the treatment of systemic lupus erythematosus and primary glomerulonephritis and agent therefor

Also Published As

Publication number Publication date
JPH0586378B2 (enExample) 1993-12-10
DE3444765A1 (de) 1985-06-20
EP0147283B1 (fr) 1989-08-16
FR2556219B1 (fr) 1987-06-26
DE147283T1 (de) 1986-04-10
EP0147283A3 (en) 1985-08-14
JPS60185726A (ja) 1985-09-21
US4719107A (en) 1988-01-12
EP0147283A2 (fr) 1985-07-03
FR2556219A1 (fr) 1985-06-14
CA1229791A (fr) 1987-12-01
DE3479398D1 (en) 1989-09-21

Similar Documents

Publication Publication Date Title
ATE45498T1 (de) Immunmodulierendes arzneimittel basiert auf fc fragmenten menschlichen ig gs.
Goldstein et al. Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide.
EP0149468B1 (de) Biologisch wirksame Substanz mit hormonellen Eigenschaften, Verfahren zu ihrer Herstellung und Verwendung von Histonen für medizinische Zwecke
Fehlmann et al. Molecular association between major histocompatibility complex class I antigens and insulin receptors in mouse liver membranes.
ATE108662T1 (de) Antimikrobielle peptide, zusammensetzungen, die diese enthalten, und verwendungen daraus.
IT8223795A0 (it) Gamma), relativi veicoli di polipeptidi contenenti la sequenza espressione, loro procedimento di degli amminoacidi dell'interferone preparazione, composizioni umano immune (interferone umano farmaceutiche contenenti tali polipeptidi.
IE45819B1 (en) Shuttle type livestock feeder
PT883687E (pt) Receptores de quimiocinas c-c, ckr-5, cc, os seus derivados e as suas utilizacoes
HU891841D0 (en) Process for preparation of amino-acid-n-carboxy-anhydrides protected with urethane group
GR81467B (enExample)
NO873699D0 (no) Polypeptid som er egnet til dempning, behandling og diagnosering av autoimmune lidelser saasom leddbetennelser.
IL75637A (en) Thymopentin analogs and pharmaceutical compositions containing them
IL72985A0 (en) Homogenous immune interferon fragment,its manufacture and pharmaceutical compositions containing it
AU548677B2 (en) Peptides derived from glucagon
KR100295606B1 (enExample)
ZA835951B (en) Novel polypeptide having an action on the immunological system,processes for its isolation and purification,its use,agents containing this compound,and its cleavage products,their use and agents containing these products
KR880011198A (ko) 사이클릭 펩타이드 및 이의 제조방법
SE7708678L (sv) Proteinhormoner
Waxman et al. The presence of specific antigen-reactive cells during the induction, recovery, and resistance phases of experimental allergic encephalomyelitis
CA2139518A1 (en) Antigenic regions of tlp complexes and antibodies against the same
AU1242188A (en) Isolation of single chain proteins with fsh suppressing activity from follicular fluid
Schmid et al. The amino acid sequences of two large glycopeptides derived from the carbohydrate-carrying region of α1-acid glycoprotein
IL106065A0 (en) Synthetic peptides for the treatment of myasthenia gravis and compositions comprising them
GB1590457A (en) Thymosin a1
Hoessli et al. Variations in the structure of surface glycoproteins present in different lymphocyte subpopulations